



**May 20, 2020**

bioMérieux, Inc.  
Attention: Ms. Mary Beth Anheuser  
595 Anglum Road  
Hazelwood, MO 63042

Re: BK200472  
Device Name: BACT/ALERT® BPA Culture Bottle  
BACT/ALERT® BPN Culture Bottle  
Regulation Number: 21 CFR 866.2560  
Regulation Name: Microbial Growth Monitor  
Regulatory Class: I, reserved  
Product Code: MZC  
Dated: March 13, 2020  
Received: March 16, 2020

Dear Ms. Anheuser:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the **Federal Register**.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Orieji Iloh, MD  
Director  
Division of Blood Components and Devices  
Office of Blood Research and Review  
Center for Biologics Evaluation and Research

Enclosure  
Indications For Use

### Indications for Use

510(k) Number: BK200472

Device Name: BACT/ALERT® BPA Culture Bottle  
BACT/ALERT® BPN Culture Bottle

#### Indications for Use:

##### BPA Culture Bottle

BACT/ALERT® BPA culture bottles are used with BACT/ALERT® Microbial Detection Systems (BACT/ALERT® 3D and BACT/ALERT® VIRTUO®) for quality control testing of leukocyte-reduced apheresis platelet (LRAP) units, and both single and pools of up to six (6) units of leukocyte-reduced whole blood platelet concentrates (LRWBPC). BACT/ALERT® BPA culture bottles support the growth of aerobic microorganisms (bacteria and fungi).

##### BPN Culture Bottle

BACT/ALERT® BPN culture bottles are used with the BACT/ALERT® Microbial Detection Systems (BACT/ALERT® 3D and BACT/ALERT® VIRTUO®) for quality control testing of leukocyte-reduced apheresis platelet (LRAP) units, and both single and pools of up to six (6) units of leukocyte-reduced whole blood platelet concentrates (LRWBPC). BACT/ALERT® BPN culture bottles support the growth of anaerobic and facultative anaerobic microorganisms (bacteria).

BACT/ALERT® Microbial Detection Systems are used to detect bacteria in platelet components.

BACT/ALERT® Microbial Detection Systems are used as a safety measure, to extend dating beyond day 5 and up to day 7 for the following (Ref. FDA guidance):

- Large volume delayed sampling (LVDS) of platelets no sooner than 48 hours after collection; OR
- Secondary culture no sooner than day 4 after platelet collection.

BACT/ALERT® Microbial Detection Systems are used to extend dating to five days for the following (Ref. FDA guidance):

- Large volume, delayed sampling of platelets no sooner than 36 hours after collection; OR
- Secondary culture no sooner than day 3 after platelet collection.

Prescription Use   X   AND/OR  
(Part 21 CFR 801 Subpart D)

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)  
Concurrence of CBER, Office of Blood Research and Review (OBRR)

\_\_\_\_\_  
Division Sign-Off, Office of Blood Research and Review